2026-2034年全球細胞和基因治療製造服務市場規模、佔有率、趨勢和成長分析報告

預計細胞和基因治療製造服務市場將從 2025 年的 157.6 億美元成長到 2034 年的 1,340.8 億美元，2026 年至 2034 年的複合年成長率為 26.86%。

由於人們對複雜疾病先進治療方法的關注度日益提高，全球細胞和基因治療生產服務市場正經歷快速成長。這些治療方法為癌症和遺傳性疾病等疾病提供了標靶治療方案，從而推動了對專業生產服務的需求。臨床試驗和監管核准的增加進一步促進了市場擴張。此外，生物技術的進步也提高了生產能力和擴充性。

關鍵促進因素包括研發投入的增加以及製藥和生技公司不斷湧入市場。外包生產服務使企業能夠降低成本並專注於創新。對個人化和再生醫學日益成長的需求也推動了市場成長。此外，生產技術的進步和監管支持也促進了這些治療方法的高效生產和商業化。

隨著更多治療方法核准上市，細胞和基因治療生產服務市場預計將迎來顯著成長。自動化和生物製程技術的進步將提升效率和擴充性。生物技術公司與契約製造組織（CMO）之間合作的加強將進一步推動創新。新興市場預計將憑藉不斷完善的醫療基礎設施和對先進治療方法的持續投入，帶來巨大的成長機會。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球細胞與基因治療製造服務市場：依治療方法

• 市場分析、洞察與預測
• 細胞療法生產（幹細胞療法、非幹細胞療法）
• 基因治療生產

第5章：全球細胞與基因治療製造服務市場：依規模分類

• 市場分析、洞察與預測
• 商業化前/研發規模生產
• 商業規模生產

第6章：全球細胞與基因治療製造服務市場：依方法分類

• 市場分析、洞察與預測
• 契約製造
• 內部生產

第7章 全球細胞與基因治療製造服務市場：依工作流程分類

• 市場分析、洞察與預測
• 細胞處理
• 細胞庫
• 製程開發
• 填充和表面處理工程
• 分析和品質測試
• 原料檢測
• 向量圖製作
• 其他

第8章 全球細胞與基因治療製造服務市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Lonza
  • Bluebird Bio Inc
  • Catalent Inc
  • F. Hoffmann-La Roche Ltd
  • Samsung Biologics
  • Boehringer Ingelheim
  • Cellular Therapeutics
  • Hitachi Chemical Co. Ltd
  • Takara Bio Inc
  • Miltenyi Biotec

The Cell & Gene Therapy Manufacturing Services Market size is expected to reach USD 134.08 Billion in 2034 from USD 15.76 Billion (2025) growing at a CAGR of 26.86% during 2026-2034.

The global cell and gene therapy manufacturing services market is experiencing rapid growth due to the increasing focus on advanced therapeutics for complex diseases. These therapies offer targeted treatment options for conditions such as cancer and genetic disorders, driving demand for specialized manufacturing services. The growing number of clinical trials and regulatory approvals is further boosting market expansion. Additionally, advancements in biotechnology are enhancing production capabilities and scalability.

Key drivers include rising investments in research and development and the increasing involvement of pharmaceutical and biotechnology companies. Outsourcing manufacturing services allows companies to reduce costs and focus on innovation. The growing demand for personalized medicine and regenerative therapies is also fueling market growth. Furthermore, improvements in manufacturing technologies and regulatory support are enabling efficient production and commercialization of these therapies.

Looking ahead, the cell and gene therapy manufacturing services market is expected to witness substantial growth as more therapies receive approval and enter the market. Technological advancements in automation and bioprocessing will improve efficiency and scalability. Increasing collaborations between biotech firms and contract manufacturing organizations will further drive innovation. Emerging markets are likely to offer significant growth opportunities due to expanding healthcare infrastructure and rising investment in advanced therapies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapy Type

• Cell Therapy Manufacturing (Stem Cell Therapy, Non-Stem Cell Therapy)
• Gene Therapy Manufacturing

By Scale

• Pre-Commercial/R&D Scale Manufacturing
• Commercial Scale Manufacturing

By Mode

• Contract Manufacturing
• In-House Manufacturing

By Workflow

• Cell Processing
• Cell Banking
• Process Development
• Fill & Finish Operations
• Analytical And Quality Testing
• Raw Material Testing
• Vector Production
• Others

COMPANIES PROFILED

• Lonza, Bluebird Bio Inc, Catalent Inc, F HoffmannLa Roche Ltd, Samsung Biologics, Boehringer Ingelheim, Cellular Therapeutics, Hitachi Chemical Co Ltd, Takara Bio Inc, Miltenyi Biotec
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Type
• 4.2. Cell Therapy Manufacturing (Stem Cell Therapy, Non-Stem Cell Therapy) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Gene Therapy Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: BY SCALE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Scale
• 5.2. Pre-Commercial/R&D Scale Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Commercial Scale Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: BY MODE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Mode
• 6.2. Contract Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. In-House Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: BY WORKFLOW 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Workflow
• 7.2. Cell Processing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Cell Banking Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Process Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Fill & Finish Operations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Analytical And Quality Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.7. Raw Material Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.8. Vector Production Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Therapy Type
  • 8.2.2 By Scale
  • 8.2.3 By Mode
  • 8.2.4 By Workflow
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Therapy Type
  • 8.3.2 By Scale
  • 8.3.3 By Mode
  • 8.3.4 By Workflow
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Therapy Type
  • 8.4.2 By Scale
  • 8.4.3 By Mode
  • 8.4.4 By Workflow
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Therapy Type
  • 8.5.2 By Scale
  • 8.5.3 By Mode
  • 8.5.4 By Workflow
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Therapy Type
  • 8.6.2 By Scale
  • 8.6.3 By Mode
  • 8.6.4 By Workflow
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Lonza
  • 10.2.2 Bluebird Bio Inc
  • 10.2.3 Catalent Inc
  • 10.2.4 F. Hoffmann-La Roche Ltd
  • 10.2.5 Samsung Biologics
  • 10.2.6 Boehringer Ingelheim
  • 10.2.7 Cellular Therapeutics
  • 10.2.8 Hitachi Chemical Co. Ltd
  • 10.2.9 Takara Bio Inc
  • 10.2.10 Miltenyi Biotec